ArticleAnnals of hematology2026
Influence of different therapy strategies in patients with myelodysplastic neoplasms (MDS) on overall survival with regard to different decades: data from the German MDS registry.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the history of myelodysplastic neoplasms (MDS), an increasing number of treatment modalities have become available. It is therefore important to assess whether these developments have translated into improved overall survival (OS) for patients. We analyzed data from 1,147 patients in the German MDS registry and observed a progressive improvement in median survival across three diagnostic periods: until 2000 (20 months), 2001-2010 (31 months), and after 2011 (57 months). Patients treated with allogeneic stem cell transplantation (SCT) had the best prognosis with a median survival of 108 months. Over time, both the proportion of patients undergoing allogeneic SCT (6.3% vs. 22.1% vs. 40.0%) and the median age at transplantation (36.5 vs. 52 vs. 61 years) increased. Notably, OS also improved among patients treated with best supportive care (BSC) alone (17 vs. 31 vs. 64 months; p < 0.001). Multivariate analysis demonstrated that the period of first diagnosis had an independent positive effect on survival. The underlying reasons for this improvement remain unclear, but a multifactorial origin-including improved supportive measures and greater eligibility for allogeneic SCT-must be considered.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.